Literature DB >> 32859635

The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk.

Li-Hsiou Chen1,2, Te-Chun Shen1,3, Chia-Hsiang Li1,3, Kuo-Liang Chiu1,2, Yu-Chen Hsiau3, Yun-Chi Wang1,3, Chi-Li Gong4, Zhi-Hong Wang5, Wen-Shin Chang1,3, Chia-Wen Tsai1,3, Te-Chun Hsia3, DA-Tian Bau6,3,7.   

Abstract

BACKGROUND: The study aims to evaluate the contribution of excision repair cross-complementing group 1 (ERCC1), which plays an important role in genome integrity maintenance, to lung cancer risk.
MATERIALS AND METHODS: ERCC1 rs11615 and rs3212986 genotypes were identified by polymerase chain reaction-restriction fragment length polymorphism analysis and their association with lung cancer risk was examined among 358 lung cancer patients and 716 controls.
RESULTS: The proportions of CC, CT and TT for the rs11615 genotype were 43.6%, 41.6% and 14.8% in the case group and 50.0%, 41.1% and 8.9% in the control group, respectively (p for trend=0.0082). Allelic analysis showed that ERCC1 rs11615 T-allele carriers have a 1.32-fold higher risk of lung cancer than wild-type C-allele carriers [95%confidence interval (CI)=1.09-1.60, p=0.0039]. In addition, a significant interaction between the rs11615 genotype and smoking status was observed.
CONCLUSION: The T allele of ERCC1 rs11615 jointly with smoking habits may contribute to a higher lung cancer risk in Taiwan. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  ERCC1; Taiwan; genotype; lung cancer; polymorphism; smoking

Mesh:

Substances:

Year:  2020        PMID: 32859635      PMCID: PMC7472448          DOI: 10.21873/cgp.20213

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  42 in total

1.  Significant Association of Interleukin-16 Genetic Variations to Taiwanese Lung Cancer.

Authors:  Meng-Feng Wu; Yun-Chi Wang; Te-Chun Shen; Wen-Shin Chang; Hsin-Ting Li; Cheng-Hsi Liao; Chi-Li Gong; Zhi-Hong Wang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use.

Authors:  Ruizhi Hou; Yan Liu; Ye Feng; Libo Sun; Zhenbo Shu; Jisheng Zhao; Shujuan Yang
Journal:  Gene       Date:  2014-05-23       Impact factor: 3.688

3.  Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.

Authors:  Cristina Pérez-Ramírez; Marisa Cañadas-Garre; Ahmed Alnatsha; Eduardo Villar; Javier Valdivia-Bautista; María José Faus-Dáder; Miguel Ángel Calleja-Hernández
Journal:  Pharmacogenomics J       Date:  2018-04-17       Impact factor: 3.550

4.  Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Authors:  J J Yu; K B Lee; C Mu; Q Li; T V Abernathy; F Bostick-Bruton; E Reed
Journal:  Int J Oncol       Date:  2000-03       Impact factor: 5.650

5.  EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.

Authors:  K-L G Spindler; R F Andersen; L H Jensen; J Ploen; A Jakobsen
Journal:  Ann Oncol       Date:  2009-10-22       Impact factor: 32.976

6.  Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer Receiving Platinum-based Chemotherapy.

Authors:  Sharareh Mokmeli; Golnaz Asaadi Tehrani; Reza Eghdam Zamiri; Tayyeb Bahrami
Journal:  Asian Pac J Cancer Prev       Date:  2016

Review 7.  DNA damage and the balance between survival and death in cancer biology.

Authors:  Wynand P Roos; Adam D Thomas; Bernd Kaina
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

8.  Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.

Authors:  Juanmei Mo; Min Luo; Jiandong Cui; Shaozhang Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.

Authors:  J Mendoza; J Martínez; C Hernández; D Pérez-Montiel; C Castro; E Fabián-Morales; M Santibáñez; R González-Barrios; J Díaz-Chávez; M A Andonegui; N Reynoso; L F Oñate; M A Jiménez; M Núñez; R Dyer; L A Herrera
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

10.  Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.

Authors:  Sandrina Lambrechts; Diether Lambrechts; Evelyn Despierre; Els Van Nieuwenhuysen; Dominiek Smeets; Philip R Debruyne; Vincent Renard; Philippe Vroman; Daisy Luyten; Patrick Neven; Frédéric Amant; Karin Leunen; Ignace Vergote
Journal:  BMC Pharmacol Toxicol       Date:  2015-02-27       Impact factor: 2.483

View more
  3 in total

1.  Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?

Authors:  Nagla Abdel Karim; Asad Ullah; Peterson Pathrose; Hassana Fathallah; Ashley Perry; John C Morris; Jiang Wang; Sandra L Starnes
Journal:  Curr Oncol       Date:  2022-07-07       Impact factor: 3.109

2.  Significant Association of Cyclin D1 Promoter Genotypes With Asthma Susceptibility in Taiwan.

Authors:  Chia-Hsiang Li; Kuo-Liang Chiu; Te-Chun Hsia; Te-Chun Shen; Li-Hsiou Chen; Chien-Chih Yu; Mei-Chin Mong; Wen-Shin Chang; Chia-Wen Tsai; DA-Tian Bau
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

3.  Significant Association of MMP2 Promoter Genotypes to Asthma Susceptibility in Taiwan.

Authors:  Li-Hsiou Chen; Kuo-Liang Chiu; Te-Chun Hsia; Yen-Hsien Lee; Te-Chun Shen; Chia-Hsiang Li; Yi-Cheng Shen; Wen-Shin Chang; Chia-Wen Tsai; DA-Tian Bau
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.